Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 3/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 7/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.30 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.30 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.30 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24549464 | 1.00 | SYK (0.37) | SYKBTKKDRKCNH2PTGES | |
| SCHEMBL24549233 | 0.94 | SYK (0.35) | SYKBTKKDRKCNH2PTGES | |
| SCHEMBL24548979 | 0.93 | SYK (0.36) | SYKBTKKDRKCNH2PTGES | |
| SCHEMBL29653762 | 0.93 | SYK (0.36) | SYKBTKKDRKCNH2PTGES | |
| SCHEMBL24549228 | 0.90 | SYK (0.38) | SYKBTKKDRKCNH2PTGES | |
| SCHEMBL24549239 | 0.89 | BTK (0.42) | SYKBTKKDRPTGESKCNN1 | |
| SCHEMBL24548986 | 0.88 | SYK (0.37) | SYKBTKKDRKCNH2PTGES | |
| SCHEMBL24549235 | 0.87 | SYK (0.38) | SYKBTKKDRKCNH2JAK2 | |
| SCHEMBL24549101 | 0.87 | TLR9 (0.42) | SYKBTKKCNH2JAK2JAK1 | |
| SCHEMBL29653724 | 0.87 | TLR9 (0.42) | SYKBTKKCNH2JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240051970-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2024-02-15 | — | — | US | disclosed |
| EP-4263531-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2022133098-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240051970-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | SYK 727/4885BTK 255/4885KDR 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.